Certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives this disease while also causing long-lasting changes in the immune system, according to a new study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
A new Cornell program will train graduate students interested in specializing in “immuno-engineering,” an emerging hybrid field that combines engineering and immunology.
Cornell researchers will use a five-year, $3.4 million grant from the National Institutes of Health to investigate whether chemical inhibitors of epigenetic regulation – including many FDA-approved drugs – could be re-purposed to treat HIV-1 infections that are persistent in tissues and represent the biggest challenge for a cure.
Dr. Hector Aguilar-Carreño, professor of virology in the Department of Microbiology and Immunology, was chosen for this fellowship due to his demonstrated success in and bright potential for leadership. He is among only nine fellows across the entire SUNY system and Cornell’s sole representative in the program.
The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells, according to a multi-institutional preclinical study led by Weill Cornell Medicine investigators.
A protein commonly found at high levels in lung cancer cells controls a major immunosuppressive pathway that allows lung tumors to evade immune attack, according to a study led by researchers at Weill Cornell Medicine.
New study finds that dietary inulin fiber alters the metabolism of certain gut bacteria, which in turn triggers what scientists call type 2 inflammation in the gut and lungs.
A new study suggests that a unique set of regulatory networks controlled by neurons in the gut may be viable targets for future drug therapies to combat chronic inflammatory diseases including asthma, allergy and inflammatory bowel disease.